Maganin Brexu-cel CAR-T Ya Nuna Sakamako Mai Kyau Ga Marasa Lafiyar R/R Na Manya

Brexucabtagene autoleucel (brexu-cel), wani maganin ƙwayoyin CD19 CAR-T, ya zama babban zaɓi na magani ga cutar sankarar jini ta B-cell mai saurin kamuwa da cutar sankarar jini ta B-cell (R/R) (B-ALL) a cikin manya. Dangane da sakamakon gwajin ZUMA-3, brexu-cel ya sami amincewa a Amurka ga manya marasa lafiya da ke fama da cutar R/R B-ALL. Duk da haka, nazarin gaske yana da mahimmanci don fahimtar ingancinsa da amincinsa a cikin aikin asibiti. Wani babban bincike da aka buga kwanan nan a cikin Mujallar Ciwon Kankara ta Asibiti yana ba da mahimman bayanai game da aikin brexu-cel a cikin ƙungiyar marasa lafiya da yawa, yana bayyana sakamako mai ƙarfafawa a cikin ƙimar gafara da rayuwa.

Bayanin Nazarin

Wannan binciken da aka yi a cibiyoyi da dama ya shafi manya 204 da ke fama da R/R B-ALL waɗanda aka yi musu magani a wajen gwaje-gwajen asibiti a cibiyoyin lafiya 31 a Amurka. Jimillar marasa lafiya 189 sun sami nasarar karɓar brexu-cel, tare da matsakaicin layukan magani guda huɗu da aka yi a baya. Kusan rabin marasa lafiyar sun riga sun yi dashen ƙwayoyin halitta na hematopoietic (HSCT), 59% sun karɓi blinatumomab, kuma 48% an yi musu magani da inotuzumab ozogamicin. A lokacin cutar leukapheresis, 42% na marasa lafiya suna cikin sassaucin yanayin jiki, wani ma'auni da zai cire su daga gwajin ZUMA-3 na asali.

Muhimman Abubuwan da aka Gano

Bayan an yi nazari na tsawon watanni 11.4, sakamakon binciken ya nuna inganci mai yawa ga brexu-cel wajen magance R/R B-ALL:

• Cikakken Amsa (CR): Kashi 90% na marasa lafiyar da aka yi wa magani sun sami cikakkiyar amsa, inda kashi 79% suka nuna ƙarancin sassaucin da ya rage musu na rashin lafiya (MRD) - wanda ba shi da alaƙa da cutar.
• Rayuwa Ba Tare da Ci Gaba Ba (PFS): Matsakaicin PFS shine watanni 9.5.
• Rayuwa ta Gabaɗaya (OS): Ba a cimma matsayar tsarin aiki na tsakiya (Median OS) ba, wanda ke nuna cewa yana da tasiri mai ɗorewa wajen tsawaita rayuwar marasa lafiya.
• Rashin daidaiton MRD: Ga marasa lafiya waɗanda aka tantance MRD ta amfani da tsarin clonoSEQ na gaba, rashin lafiyar MRD a rana ta 28 yana da alaƙa da ingantaccen PFS da OS, wanda ke ƙarfafa ƙimar MRD a matsayin alamar hasashen.

Tasirin Maganin Haɗaka

Binciken ya kuma gano cewa marasa lafiya da suka sami HSCT mai ƙarfi bayan maganin brexu-cel suna da PFS mafi kyau idan aka kwatanta da waɗanda ba a yi musu wani magani na haɗin gwiwa ko kulawa ba. A cikin wani bincike mai yawa, HSCT (wanda aka yi wa marasa lafiya 30) bayan CAR-T yana da alaƙa da raguwar haɗarin ci gaban cututtuka (HR=0.34).

Bayanin Tsaro

Duk da ingancinsa, maganin brexu-cel ya gabatar da manyan abubuwan da suka faru, waɗanda suke da mahimmanci a cikin kula da asibiti:

• Ciwon Sakin Cytokine (CRS) da Gubar Jiki (ICANS): An ruwaito CRS a cikin kashi 84% na marasa lafiya, tare da manyan lamuran (aji na 3-4) a cikin kashi 11%. ICANS sun faru a cikin kashi 56% na marasa lafiya, tare da manyan lamuran a cikin kashi 31%.
• Mutuwa da Mutuwar da Ba ta Dawowa Ba: Kashi talatin da huɗu cikin ɗari na marasa lafiya sun mutu a lokacin binciken, inda kashi 13 cikin ɗari na mace-macen da ba su da alaƙa da ci gaban cutar sankarar bargo. Marasa lafiya goma sun mutu a cikin kwanaki 28 na farko bayan an yi musu magani saboda guba ko kamuwa da cuta, musamman a tsakanin waɗanda ke da yawan kamuwa da cuta. Cututtukan fungal su ne suka fi yawan mace-macen da suka shafi kamuwa da cuta, wanda ke nuna buƙatar kula da kamuwa da cuta a hankali.

Kammalawa

Sakamakon wannan binciken na zahiri ya yi daidai da sakamakon gwajin ZUMA-3, yana tabbatar da yawan CR mai cutar MRD-negative na brexu-cel da kuma sakamakon rayuwa mai kyau ga manya marasa lafiya da ke fama da R/R B-ALL. Duk da haka, manyan guba, musamman ICANS masu tsanani da mace-mace da wuri, sun nuna mahimmancin dabarun rage haɗari, gami da rigakafin kamuwa da cuta da kuma sa ido sosai. Bugu da ƙari, an nuna cewa amfani da maganin HSCT mai haɗin gwiwa bayan CAR-T yana inganta rayuwa ba tare da ci gaba ba, yana ba da damar ingantacciyar hanyar inganta sakamakon marasa lafiya.

Wannan binciken ya jaddada rawar da brexu-cel ke takawa a matsayin magani na yau da kullun ga manya R/R B-ALL yayin da yake jaddada ƙalubalen da ke ci gaba da fuskanta wajen sarrafa illolinsa.